Moderna shares soar as mRNA cancer vaccine succeeds in late-stage trialProactive Investors • 08/19/26
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full resultsReuters • 08/19/26
Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial24/7 Wall Street • 08/19/26
Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks SoarBenzinga • 08/19/26
Moderna Skyrockets 100%, Merck Jumps On Late-Stage Cancer Vaccine Trial WinInvestors Business Daily • 08/19/26
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trialCNBC • 08/19/26
An experimental mRNA-based cancer vaccine succeeded in preventing melanoma from coming back or spreading in a large study, partners Merck and Moderna said.WSJ • 08/19/26
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV MelanomaBusiness Wire • 08/19/26
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline MilestonesZacks Investment Research • 08/07/26
Moderna Wavers Despite Hard-Fought FDA Win; Will Its Sprint Restart?Investors Business Daily • 08/06/26
Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic FutureBarrons • 08/06/26